BridgeBio Pharma Net Worth
BridgeBio Pharma Net Worth Breakdown | BBIO |
BridgeBio Pharma Net Worth Analysis
BridgeBio Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including BridgeBio Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of BridgeBio Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform BridgeBio Pharma's net worth analysis. One common approach is to calculate BridgeBio Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares BridgeBio Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing BridgeBio Pharma's net worth. This approach calculates the present value of BridgeBio Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of BridgeBio Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate BridgeBio Pharma's net worth. This involves comparing BridgeBio Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into BridgeBio Pharma's net worth relative to its peers.
To determine if BridgeBio Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BridgeBio Pharma's net worth research are outlined below:
| BridgeBio Pharma had very high historical volatility over the last 90 days | |
| BridgeBio Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 9.3 M. Net Loss for the year was (643.2 M) with profit before overhead, payroll, taxes, and interest of 74.21 M. | |
| BridgeBio Pharma currently holds about 715.71 M in cash with (527.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83. | |
| Over 94.0% of the company shares are held by institutions such as insurance companies |
BridgeBio Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BridgeBio Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BridgeBio Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow BridgeBio Pharma's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.31 B.Project BridgeBio Pharma's profitablity
The company has Profit Margin (PM) of (2.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (68.5) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $68.5.When accessing BridgeBio Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures BridgeBio Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BridgeBio Pharma's profitability and make more informed investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BridgeBio Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on BridgeBio Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BridgeBio Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BridgeBio Pharma time-series forecasting models is one of many BridgeBio Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BridgeBio Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BridgeBio Pharma Earnings per Share Projection vs Actual
BridgeBio Pharma Corporate Management
| Neil Kumar | President, CoFounder | Profile | |
| MBA CPC | Chief Officer | Profile | |
| Eli Wallace | Chief Oncology | Profile | |
| Frank McCormick | CoFounder Oncology | Profile | |
| Thomas Trimarchi | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.